Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensia-Aldo: Intensive vs Standard BP Control in Primary Aldosteronism
NCT07673445Recruiting
- Sponsor
- Chongqing Medical University
- Start
- Jul 2026
- Primary completion
- Dec 2036
- Countries
- 1
01
Overview
Randomised, open-label trial in primary aldosteronism (PA) (2 arms), sponsored by Chongqing Medical University. Primary endpoint: Number of composite cardiovascular events. Started Jul 2026; status: recruiting.
02
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on NCT07673445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07673445.